Subscribe To
INAB / IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment
INAB News
By GlobeNewsWire
November 2, 2023
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta more_horizontal
By Zacks Investment Research
June 5, 2023
IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross
IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day more_horizontal
By Zacks Investment Research
May 24, 2023
IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal
By PennyStocks
May 2, 2023
Stock Market Today: Penny Stocks To Watch Amid Banking Crisis
Penny stocks to watch as bank stocks fall in the stock market today. The post Stock Market Today: Penny Stocks To Watch Amid Banking Crisis appeared f more_horizontal
By InvestorPlace
April 26, 2023
Why Is IN8bio (INAB) Stock Up 9% Today?
IN8bio (NASDAQ: INAB ) stock is rising higher on Wednesday as the company's shares continue their wild swings this week. The strong movement for the s more_horizontal
By Proactive Investors
April 25, 2023
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment
IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan more_horizontal
By InvestorPlace
April 25, 2023
What Is Going on With In8bio (INAB) Stock Today?
In8bio (NASDAQ: INAB ) stock is on the move Tuesday as investors react to a recent rally and additional news from the biotechnology company. First off more_horizontal
By GlobeNewsWire
April 11, 2023
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innova more_horizontal